Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials
Clinical Trials · 2024
DOI: 10.1177/17407745231203330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Trials, 2024. Verfasst von R Taylor Sundby und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA. Hauptthemen laut MEDLINE: Neurofibromatosis 1, Neurofibromatosis 2, Neurofibromatoses, Neurilemmoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NINDS NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Introduction
Neurofibromatosis 1 and schwannomatosis are characterized by potential lifelong morbidity and life-threatening complications. To date, however, diagnostic and predictive biomarkers are an unmet need in this patient population. The inclusion of biomarker discovery correlatives in neurofibromatosis 1/schwannomatosis clinical trials enables study of low-incidence disease. The implementation of a common data model would further enhance biomarker discovery by enabling effective concatenation of data from multiple studies.
Methods
The Response Evaluation in Neurofibromatosis and Schwannomatosis biomarker working group reviewed published data on emerging trends in neurofibromatosis 1 and schwannomatosis biomarker research and developed recommendations in a series of consensus meetings.
Results
Liquid biopsy has emerged as a promising assay for neurofibromatosis 1/schwannomatosis biomarker discovery and validation. In addition, we review recommendations for a range of biomarkers in clinical trials, neurofibromatosis 1/schwannomatosis–specific data annotations, and common data models for data integration.
Conclusion
These Response Evaluation in Neurofibromatosis and Schwannomatosis consensus guidelines are intended to provide best practices for the inclusion of biomarker studies in neurofibromatosis 1/schwannomatosis clinical trials, data, and sample annotation and to lay a framework for data harmonization and concatenation between trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA.
- Division of Hematology/Oncology/Stem Cell Transplant, Department of Pediatrics, Herman B Wells Center for Pediatric Research, School of Medicine, Indiana University, Indianapolis, IN, USA.
- Department of Neurology, MedStar Georgetown University Hospital, Washington, DC, USA.
- Research and Development, Infixion Bioscience, Inc., San Diego, CA, USA.
- Patient Representative, REiNS International Collaboration, San Diego, CA, USA.
- Neural Stem Cell Institute, Rensselaer, NY, USA.
ORCID-Profile: R Taylor Sundby
Förderung
- NIH HHS
- NINDS NIH HHS
- NCI NIH HHS
- Intramural NIH HHS
Zitieren
APA
Sundby, R. T., Rhodes, S. D., Komlodi-Pasztor, E., Sarnoff, H., Grasso, V., Upadhyaya, M., Kim, A., Evans, D. G., Blakeley, J. O., Hanemann, C. O., & Bettegowda, C. (2024). Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials. Clinical Trials. https://doi.org/10.1177/17407745231203330
Vancouver
Sundby RT, Rhodes SD, Komlodi-Pasztor E, Sarnoff H, Grasso V, Upadhyaya M, et al. Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials. Clinical Trials. 2024. doi:10.1177/17407745231203330
BibTeX
@article{Sundby2024,
author = {Sundby, R Taylor and Rhodes, Steven D and Komlodi-Pasztor, Edina and Sarnoff, Herb and Grasso, Vito and Upadhyaya, Meena and Kim, AeRang and Evans, D Gareth and Blakeley, Jaishri O and Hanemann, C Oliver and Bettegowda, Chetan},
title = {Recommendations for the collection and annotation of biosamples for analysis of biomarkers in neurofibromatosis and schwannomatosis clinical trials},
journal = {Clinical Trials},
year = {2024},
doi = {10.1177/17407745231203330}
}
EUVIMED